search.noResults

search.searching

saml.title
dataCollection.invalidEmail
note.createNoteMessage

search.noResults

search.searching

orderForm.title

orderForm.productCode
orderForm.description
orderForm.quantity
orderForm.itemPrice
orderForm.price
orderForm.totalPrice
orderForm.deliveryDetails.billingAddress
orderForm.deliveryDetails.deliveryAddress
orderForm.noItems
Infection prevention


diagnostic services are integrated effectively across different care settings. Their role in enabling safe and sustainable expansion of point- of-care testing is becoming ever more important. There is also a wider public health


responsibility at play. Infection diagnostics sit at the heart of tackling antimicrobial resistance (AMR); one of the most significant healthcare challenges facing societies globally. When clinicians have access to timely and accurate diagnostic information, uncertainty is reduced. As uncertainty decreases, so too does the need for precautionary or inappropriate antibiotic prescribing. Supporting healthcare professionals with evidence-based insight is one of the most practical ways to strengthen antimicrobial stewardship efforts and protect the effectiveness of antibiotics for future generations. Importantly, the conversation extended


beyond clinical outcomes and operational efficiency to consider equity. Access to timely diagnosis remains inconsistent across different regions, communities and care settings. Patients should not experience differences in care because of where they live or where they enter the healthcare system. Bringing diagnostics closer to patients presents an important opportunity to address these inequalities and create a more consistent standard of care across the NHS. Whether through community diagnostic services, virtual wards, primary care settings or integrated neighbourhood teams, expanding access to testing can help ensure that more patients benefit from rapid decision-making without needing to navigate complex referral pathways or travel significant distances for care. So, where do we go from here? If “the right test, right time” is the ambition, achieving it will require more than innovation alone. It will require alignment across the health system, bringing together clinical leadership, laboratory expertise, commissioners, policymakers and industry partners to redesign care pathways around the needs of patients, rather than organisational boundaries. It will require a willingness to move beyond successful pilots and localised examples of excellence towards sustained, system- wide adoption. That means establishing clear accountability, developing integrated pathways, supporting workforce development and ensuring that funding mechanisms and incentives enable rather than hinder innovation. Most importantly, it will require collaboration. Because ultimately, this conversation is about far more than diagnostics. It is about


how the NHS intends to deliver care in the decade ahead: faster, closer to home, more equitable, more resilient and more sustainable. Diagnostics are not the destination, but they are a critical part of the journey. The direction is clear. The evidence is growing.


About the author


Lauren Campbell is the Point of Care Product Manager at bioMérieux – a family-owned company, established in 1963. The company develops and produces diagnostic solutions that help healthcare professionals quickly and reliably determine a pathology or the source of a contamination and provide them with crucial information for optimal patient care.


The ambition is widely shared. The question now is how quickly the system can move from intent to implementation and ensure that every patient, regardless of location or setting, can benefit from the right test, at the right time, in the right place.


CSJ


The patient is out of the woods. But you don’t let your guard down.


Infection risk can happen when you least expect it – even in one connection. The MicroClave™


Clear IV connector offers clinically


differentiated protection without disrupting established practice. Because out of the woods doesn’t mean out of risk. Compatible with certain glass syringes.


To learn more, visit icumed.com/clavetech


Check with the syringe manufacturer to confirm compatibility.


The product complies with current legislation and has the corresponding CE marking. For additional information, warnings and/or safety precautions, refer to the manufacturer’s Instructions for Use.


© 2026 ICU Medical, Inc. | P26-8570


September 2026 I www.clinicalservicesjournal.com 59


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85